Northland Capital Markets Remains Sidelined on Heartware (HTWR) Following Recent Checks

Northland Capital Markets reiterated a Market Perform rating and $45.00 price target on Heartware Int'l (NASDAQ: HTWR) following recent field checks. Checks indicate that the HM-III has quickly gained 50% share in some higher-volume German centers. Clinicians who have implanted HM-III using a thoracotomy approach have indicated that it is "not bad" to implant.

Analyst Suraj Kalia commented, "Entering FY16, we remain concerned about the fundamental risk-reward scenario
for Heartware. Beneath are our thoughts, combined with some recent field checks."

For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.

Shares of Heartware Int'l closed at $50.40 yesterday.

You May Also Be Interested In

• Marvell (MRVL) PT Raised to $225 at TD Cowen
• Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets
• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at H.C. Wainwright